Tools
Tools
Abhishek, Abhishek, Boyton, Rosemary J., Peckham, Nicholas, McKnight, Áine, Coates, Laura C., Bluett, James, Barber, Vicki, Cureton, Lucy, Francis, Anne, Appelbe, Duncan, Eldridge, Lucy, Julier, Patrick, Valdes, Ana M., Brooks, Tim, Rombach, Ines, Altmann, Daniel M., Nguyen-Van-Tam, Jonathan S., Williams, Hywel C., Cook, Jonathan A., Gaffney, Karl 
ORCID: https://orcid.org/0000-0002-7863-9176, Lapin, Agnieszka, Levell, Nick ORCID: https://orcid.org/0000-0003-3393-8305, Lim, Edwin and Pradeep, John
and
VROOM study investigators
(2022)
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial.
The Lancet Respiratory Medicine, 10 (9).
pp. 840-850.
ISSN 2213-2600
Preview |
PDF (1-s2.0-S2213260022001862-main)
- Published Version
Available under License Creative Commons Attribution. Download (1MB) | Preview |
Abstract
Background: Immunosuppressive treatments inhibit vaccine-induced immunity against SARS-CoV-2. We evaluated whether a 2-week interruption of methotrexate treatment immediately after the COVID-19 vaccine booster improved antibody responses against the S1 receptor-binding domain (S1-RBD) of the SARS-CoV-2 spike protein compared with uninterrupted treatment in patients with immune-mediated inflammatory diseases. Methods: We did an open-label, prospective, two-arm, parallel-group, multicentre, randomised, controlled, superiority trial in 26 hospitals in the UK. We recruited adults from rheumatology and dermatology clinics who had been diagnosed with an immune-mediated inflammatory disease (eg, rheumatoid arthritis, psoriasis with or without arthritis, axial spondyloarthritis, atopic dermatitis, polymyalgia rheumatica, and systemic lupus erythematosus) and who were taking low-dose weekly methotrexate (≤25 mg per week) for at least 3 months. Participants also had to have received two primary vaccine doses from the UK COVID-19 vaccination programme. We randomly assigned the participants (1:1), using a centralised validated computer randomisation program, to suspend methotrexate treatment for 2 weeks immediately after their COVID-19 booster (suspend methotrexate group) or to continue treatment as usual (continue methotrexate group). Participants, investigators, clinical research staff, and data analysts were unmasked, while researchers doing the laboratory analyses were masked to group assignment. The primary outcome was S1-RBD antibody titres 4 weeks after receiving the COVID-19 booster vaccine dose, assessed in the intention-to-treat population. This trial is registered with ISRCT, ISRCTN11442263; following the pre-planned interim analysis, recruitment was stopped early. Findings: Between Sept 30, 2021 and March 3, 2022, we recruited 340 participants, of whom 254 were included in the interim analysis and had been randomly assigned to one of the two groups: 127 in the continue methotrexate group and 127 in the suspend methotrexate group. Their mean age was 59·1 years, 155 (61%) were female, 130 (51%) had rheumatoid arthritis, and 86 (34%) had psoriasis with or without arthritis. After 4 weeks, the geometric mean S1-RBD antibody titre was 22 750 U/mL (95% CI 19 314–26 796) in the suspend methotrexate group and 10 798 U/mL (8970–12 997) in the continue methotrexate group, with a geometric mean ratio (GMR) of 2·19 (95% CI 1·57–3·04; p<0·0001; mixed-effects model). The increased antibody response in the suspend methotrexate group was consistent across methotrexate dose, administration route, type of immune-mediated inflammatory disease, age, primary vaccination platform, and history of SARS-CoV-2 infection. There were no intervention-related serious adverse events. Interpretation: A 2-week interruption of methotrexate treatment for people with immune-mediated inflammatory diseases resulted in enhanced boosting of antibody responses after COVID-19 vaccination. This intervention is simple, low-cost, and easy to implement, and could potentially translate to increased vaccine efficacy and duration of protection for susceptible groups. Funding: National Institute for Health and Care Research.
| Item Type: | Article |
|---|---|
| Additional Information: | Funding Information: The study was funded by the National Institute for Health Research (NIHR) Efficacy Mechanism Evaluation programme, grant number NIHR134607. Support was also received from the NIHR Oxford Biomedical Research Centre. The views expressed in this document are those of the authors and not necessarily those of the NIHR, the Department of Health and Social Care, or the Joint Committee on Vaccination and Immunisation. The study is sponsored by the University of Nottingham (Nottingham, UK) and is managed by the Oxford Clinical Trials Research Unit. The co-authors would like to acknowledge the funders and the contribution of Patient and Public Involvement volunteers in Oxford and Nottingham for their help in designing this study and members of Oxford Clinical Trials Research Unit who enabled the rapid set-up and have provided ongoing support for this study. The views expressed in this Article are those of its authors and not necessarily those of the Department of Health and Social Care or the Joint Committee on Vaccination and Immunisation. © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license |
| Uncontrolled Keywords: | pulmonary and respiratory medicine,sdg 3 - good health and well-being ,/dk/atira/pure/subjectarea/asjc/2700/2740 |
| Faculty \ School: | Faculty of Medicine and Health Sciences > Norwich Medical School |
| Related URLs: | |
| Depositing User: | LivePure Connector |
| Date Deposited: | 03 Jun 2024 11:31 |
| Last Modified: | 27 Nov 2024 10:43 |
| URI: | https://ueaeprints.uea.ac.uk/id/eprint/95369 |
| DOI: | 10.1016/S2213-2600(22)00186-2 |
Downloads
Downloads per month over past year
Actions (login required)
 |
View Item |